Optimer Pharmaceuticals (OPTR) Posts Q3 Loss of $0.28, 9c Better than Views
OPTR Hot Sheet
Revenue Growth %: -79.2%Financial Fact:
Research and development: 11.07M
Today's EPS Names:
TARO, BRLI, TLB, More
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) reports Q3 loss of $0.28, 9 cents better than the analyst estimate of ($0.37). Revenue for the quarter was $176,202, which compares to the estimate of $210,000.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
